AZRX AzurRx BioPharma

Employees

Data from SEC filings
Employee count

Shareholder alignment

Proxy contests and exempt solicitations in last 3 years

No recent proxy contest or exempt solicitation filings from shareholders.

Vote support at last AGM
On September 11, 2020, AzurRx BioPharma, Inc. (the “Company”) held its Annual Meeting of Stockholders (the “Annual Meeting”). The matters voted on at the Annual Meeting were: (1) the election of directors, (2) the approval of the issuance of more than 20% of shares of common stock, par value $0.0001 per share (the “Common Stock”) pursuant to a private placement (the “Private Placement”) and related exchange transaction (the “Exchange”), for purposes of Nasdaq listing Rule 5635(d), (3) the approval of the issuance of shares of Common Stock to certain officers and directors in the Private Placement and the Exchange, for purposes of Nasdaq Listing Rule 5635(c), (4) the approval of the issuance of more than 20% of Common Stock pursuant to a purchase agreement with Lincoln Park Capital Fund, LLC, for purposes of Nasdaq Listing Rule 5635(d), (5) the approval of the AzurRx BioPharma, Inc. 2020 Omnibus Equity Incentive Plan, (6) the ratification of the appointment of Mazars USA LLP as the Company’s independent registered public accounting firm for the Company’s fiscal year ending December 31, 2020 and (7) the approval of the adjournment of the Annual Meeting to the extent there are insufficient proxies at the Annual Meeting to approve any one or more of the foregoing proposals. The final voting results were as follows:
1.
The election of each of Edward J. Borkowski, Charles J. Casamento, Alastair Riddell, Vern L. Schramm, James Sapirstein and Gregory Oakes as directors to hold office for a term of one year, until his or her successor is duly elected and qualified or he or she is otherwise unable to complete his or her term.
The votes were cast for this matter as follows:
NomineesVotes ForVotes WithheldBroker Non-Votes
Edward J. Borkowski8,158,7574,921,7199,250,263
Charles J. Casamento8,937,8424,142,6349,250,263
Alastair Riddell9,631,7143,448,7629,250,263
Vern L. Schramm10,975,2912,105,1859,250,263
James Sapirstein10,539,7372,540,7399,250,263
Gregory Oakes10,609,2622,471,2149,250,263
2.
The proposal to approve the issuance of more than 20% of the Common Stock pursuant to the Private Placement and the Exchange, for purposes of Nasdaq Listing Rule 5635(d), was approved based upon the following votes:
Votes ForVotes AgainstAbstentionsBroker Non-Votes
12,131,484857,88491,1089,250,263
3.
The proposal to approve the issuance of shares of Common Stock to certain officers and directors in the Private Placement and the Exchange, for purposes of Nasdaq Listing Rule 5635(c), was approved based upon the following votes:
Votes ForVotes AgainstAbstentionsBroker Non-Votes
9,123,6313,751,966204,879
9,250,263
4.
The proposal to approve the issuance of more than 20% of the Company Stock pursuant to a purchase agreement with Lincoln Park Capital Fund, LLC, for purposes of Nasdaq Listing Rule 5635(d), was approved based upon the following votes:
Votes ForVotes AgainstAbstentionsBroker Non-Votes
11,883,3231,023,696173,4579,250,263
5.
The proposal approve the AzurRx BioPharma, Inc. 2020 Omnibus Equity Incentive Plan was approved based upon the following votes:
Votes ForVotes AgainstAbstentionsBroker Non-Votes
7,867,1104,940,712272,6549,250,263
6.
The proposal to ratify the appointment of Mazars USA LLP as the Company’s independent registered public accounting firm for the Company’s fiscal year ending December 31, 2020 was approved based upon the following votes:
Votes ForVotes AgainstAbstentions
21,836,065380,991113,683
7.
The proposal to approve the adjournment of the Annual Meeting to the extent that there are insufficient proxies at the Annual Meeting to approve any one or more of the foregoing proposals was approved based upon the following votes:
Votes ForVotes AgainstAbstentions
18,639,1673,380,217311,355